Is repurposing just serendipity?
Like Ore Pharmaceuticals, Melior’s business is also rooted in drug repositioning. And, like Ore, it is their technology that allows them to provide repositioning services to their business partners. Specifically, Melior\’s technology is “a platform comprised of 35 animal models (disease models) representing a broad range of therapeutic areas,” says Reaume. Melior tests a partner\’s compound against all of these disease models to uncover unexpected uses in a “non-hypothesis driven” manner—a system that has been successful both in their own drug discovery efforts, as well as in the company\’s collaborations with pharma and biotech partners. “Once we have their compounds, we perform preliminary work, which consists of a reasonably thorough pharmacokinetics and maximum tolerated dose analysis to very carefully describe the in vivo qualities of these compounds, which in turn allow us to design custom-dosing regimens for these compounds,” says Reaume. Then, multiple doses are administered to
